Radiprodil

Radiprodil
Clinical data
Other namesRGH-896; RGH896
Routes of
administration
Oral
Drug classNR2B subunit-containing NMDA receptor negative allosteric modulator
Identifiers
  • 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H20FN3O4
Molar mass397.406 g·mol−1
3D model (JSmol)
  • C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
  • InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
  • Key:GKGRZLGAQZPEHO-UHFFFAOYSA-N

Radiprodil (INNTooltip International Nonproprietary Name; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.